MedTrace Logo

OSI-774 (Tarceva) in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

NCT00036647 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 731

Last updated 2018-01-10

No results posted yet for this study

Summary

The purpose of this study is to determine if OSI-774 will improve overall survival of patients with incurable stage IIIB/IV non-small cell lung cancer compared to standard of care. OSI-774 is a new type of drug under evaluation called an epidermal growth factor receptor (EGFR). OSI-774 is an investigational drug that has not yet been approved by the U.S. Food and Drug Administration (FDA).

Conditions

  • Carcinoma, Non-small-cell Lung

Interventions

DRUG

Tarceva (erlotinib HCl, OSI-774 )

Sponsors & Collaborators

  • Canadian Cancer Trials Group

    collaborator NETWORK

  • OSI Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Frances Shephard, M.D. · Princess Margaret Hospital, Canada

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2001-11-01
Primary Completion
2004-01-30
Completion
2004-01-30

Countries

  • United States
  • Argentina
  • Australia
  • Brazil
  • Canada
  • Chile
  • China
  • Germany
  • Greece
  • Israel
  • Mexico
  • New Zealand
  • Romania
  • Singapore
  • South Africa
  • Sweden
  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00036647 on ClinicalTrials.gov